Bicycle Therapeutics PLC expected to post a loss of 43 cents a share - Earnings Preview

Bicycle Therapeutics

26/10/2026 13:02

Bicycle Therapeutics PLC BCYC.OQ BCYC.O is expected to  show a fall in quarterly revenue when it reports  results on October 28 (estimated) for the period ending September 30 2026
The Cambridge Cambridgeshire-based  company is expected to report a 48.3% decrease in revenue to $6.069 million from $11.73 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Bicycle Therapeutics PLC is for a loss of 43 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $11.00, about 209.9% above its last closing price of $3.55
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.61
-0.58
-0.72
Missed
-25.1
Mar. 31 2026
-0.60
-0.62
-0.87
Missed
-40.1
Dec. 31 2025
-0.86
-0.94
-0.29
Beat
69.1​
Sep. 30 2025
-1.10
-1.08
-0.85
Beat
21.1
​​Jun. 30 2025
-0.97
-0.95
-1.14
Missed
-19.8
Mar. 31 2025
-0.82
-0.84
-0.88
Missed
-4.5​
Dec. 31 2024
-0.82
-0.86
-0.82
Beat
4.5
Sep. 30 2024
-0.75
-0.78
-0.74
Beat
5.3
This summary was machine generated October 26 at 13:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)